Studies related to Triglycerides and Benfotiamine

A Double-blind, Randomized, Placebo-controlled Clinical Trial On Benfotiamine Treatment In Patients With Diabetic Nephropathy

Effect None
Trial Design Double blind
Trial Length n/a
Number of Subjects 63
Gender Both Genders
Age Range 45-64, 65+
Body Types Obese
Notes for this study:
In diabetic persons with 10-12 years of diabetes who failed to respond to ACE inhibitors or ARB therapy who were given 900mg benfotiamine (3x300mg) for 12 weeks failed to find any significant benefit of supplementation.